[EN] HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA<br/>[FR] PIPERAZINES HETEROCYCLIQUES SUBSTITUEES POUR LE TRAITEMENT DE LA SCHIZOPHRENIE
申请人:WARNER LAMBERT CO
公开号:WO2004026864A1
公开(公告)日:2004-04-01
This invention relates to compounds of the formula 1 wherein X, Y, Z, A, R', R2, R3, R4, R9, W' and W2 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.
Heterocyclic substituted piperazines for the treatment of schizophrenia
申请人:——
公开号:US20040138230A1
公开(公告)日:2004-07-15
This invention relates to compounds of the formula 1
1
wherein X, Y, Z, A, R
1
, R
2
, R
3
, R
4
, R
9
, W
1
and W
2
are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.
transducers and activators of transcription 5A and 5B (STAT5A and STAT5B) are two closely related STAT family members that are crucial downstream effectors of tyrosine kinase oncoproteins such as FLT3‐ITD in acute myeloid leukemia (AML) and BCR‐ABL in chronic myeloid leukemia (CML). We recently developed and reported the synthesis of a first molecule called 17 f that selectivelyinhibits STAT5 signaling in myeloid